Rigel Pharmaceuticals (RIGL) Short Interest Ratio & Short Volume

Short interest is the volume of Rigel Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 8,100,000 shares of RIGL short. Learn More on Rigel Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RIGL shares currently have a short interest ratio of 3.0. Learn More on Rigel Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Rigel Pharmaceuticals: Susquehanna International Group LLP, and Group One Trading L.P.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Rigel Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 8,100,000 shares, a decrease of 4.8% from the previous total of 8,510,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Rigel Pharmaceuticals: Spectrum Pharmaceuticals, Inc. (1.50%), Verastem, Inc. (5.87%), XOMA Co. (4.98%), Merrimack Pharmaceuticals, Inc. (5.05%), Vanda Pharmaceuticals Inc. (5.19%), Fortress Biotech, Inc. (0.79%), Bolt Biotherapeutics, Inc. (6.40%), Emergent BioSolutions Inc. (14.37%), Intercept Pharmaceuticals, Inc. (9.05%), Lexicon Pharmaceuticals, Inc. (3.40%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks.

Short selling RIGL is an investing strategy that aims to generate trading profit from Rigel Pharmaceuticals as its price is falling. RIGL shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Rigel Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RIGL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RIGL, twice per month. The most recent reporting period available is May, 15 2023.